In contrast, similar novel IL-17 inhibitors (IXE, SEC) are tested in distinctly fewer studies with smaller enrollments, which might be due to a limited application field in ERA and JPsA concerning JIA. Here, IL17A is linked to juvenile idiopathic arthritis.